Squarepoint Ops LLC Makes New $120,000 Investment in PDS Biotechnology Co. (NASDAQ:PDSB)

Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 40,979 shares of the company’s stock, valued at approximately $120,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of PDS Biotechnology by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL raised its holdings in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares in the last quarter. Inspirion Wealth Advisors LLC raised its holdings in shares of PDS Biotechnology by 5.5% in the 1st quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock worth $1,406,000 after purchasing an additional 18,383 shares in the last quarter. Tempus Wealth Planning LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth approximately $55,000. Finally, Ground Swell Capital LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth approximately $67,000. 26.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PDSB has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Wednesday, October 2nd. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, PDS Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

PDS Biotechnology Stock Performance

PDSB stock opened at $3.42 on Monday. The firm has a 50 day moving average of $3.24 and a two-hundred day moving average of $3.29. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology Co. has a 12 month low of $2.53 and a 12 month high of $6.85. The company has a market capitalization of $125.44 million, a price-to-earnings ratio of -2.51 and a beta of 1.90.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter last year, the firm earned ($0.37) earnings per share. As a group, equities analysts anticipate that PDS Biotechnology Co. will post -1.24 EPS for the current fiscal year.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.